Lenvatinib Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Lenvatinib clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Hepatocellular CarcinomaLenvatinibTranscatheter Arterial Chemoembolization+1 more
Sun Yat-sen University32 enrolled1 locationNCT06740370
Recruiting
Phase 2

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Hepatocellular CarcinomaTislelizumabOxaliplatin+3 more
Zhejiang Cancer Hospital35 enrolled1 locationNCT05920863
Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular CarcinomaPD-1 InhibitorLenvatinib+1 more
Sun Yat-sen University300 enrolled1 locationNCT06333561
Recruiting
Not Applicable

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

AblationSystemic TherapyRecurrent Hepatocellular Carcinoma+2 more
Sun Yat-sen University116 enrolled1 locationNCT06609850
Recruiting

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

PD-1Systemic TherapyLenvatinib+3 more
First Hospital of China Medical University84 enrolled1 locationNCT06632093
Recruiting
Not Applicable

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Hepatocellular CarcinomaImmunotherapyCamrelizumab+2 more
Sun Yat-sen University40 enrolled1 locationNCT06061276
Recruiting
Not Applicable

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University60 enrolled1 locationNCT06550921
Recruiting
Not Applicable

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Hepatocellular CarcinomaImmunotherapySintilimab+2 more
Sun Yat-sen University30 enrolled1 locationNCT06070636
Recruiting
Phase 2

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Cadonilimab and Lenvatinib
Peking Union Medical College Hospital30 enrolled1 locationNCT06215651
Recruiting
Early Phase 1

Using Chronobiology to Improve Lenvatinib Efficacy

Lenvatinib Treatment
Hadassah Medical Organization10 enrolled1 locationNCT06321120
Recruiting
Not Applicable

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

Liver CancerHepatocellular CarcinomaRecurrent Tumor+2 more
Sun Yat-sen University274 enrolled1 locationNCT05444478